Deerfield Management ACCD Position
ExitedDeerfield Management exited their position in Accolade Inc. (ACCD) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
1 other tracked fund also holds ACCD.
About Accolade Inc.
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Full company profile →Deerfield Management ACCD Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q1 2025 | Exited | 0 | -3,475,000 | $0 |
| Q4 2024 | Held | 3,475,000 | — | $11.9M |
| Q3 2024 | Held | 3,475,000 | — | $13.4M |
| Q2 2024 | Increased | 3,475,000 | +1,092,898 | $12.4M |
| Q1 2024 | Decreased | 2,382,102 | -130,215,898 | $25.0M |
| Q4 2023 | Held | 132,598,000 | — | $114.0M |
| Q3 2023 | Increased | 132,598,000 | +10,000,000 | $107.9M |
| Q2 2023 | Held | 122,598,000 | — | $102.1M |
| Q1 2023 | New | 122,598,000 | +122,598,000 | $96.6M |
Frequently Asked Questions
Does Deerfield Management own ACCD?
No. Deerfield Management exited their position in Accolade Inc. (ACCD) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own ACCD?
1 specialist biotech hedge fund currently holds ACCD, including Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ACCD?
Deerfield Management's position in ACCD was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ACCD position increasing or decreasing?
Deerfield Management completely exited their ACCD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ACCDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →